These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

574 related items for PubMed ID: 25392999

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia.
    Beck H, Jeske M, Thede K, Stoll F, Flamme I, Akbaba M, Ergüden JK, Karig G, Keldenich J, Oehme F, Militzer HC, Hartung IV, Thuss U.
    ChemMedChem; 2018 May 23; 13(10):988-1003. PubMed ID: 29485740
    [Abstract] [Full Text] [Related]

  • 4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
    Del Balzo U, Signore PE, Walkinshaw G, Seeley TW, Brenner MC, Wang Q, Guo G, Arend MP, Flippin LA, Chow FA, Gervasi DC, Kjaergaard CH, Langsetmo I, Guenzler V, Liu DY, Klaus SJ, Lin A, Neff TB.
    J Pharmacol Exp Ther; 2020 Aug 23; 374(2):342-353. PubMed ID: 32487538
    [Abstract] [Full Text] [Related]

  • 5. The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.
    Nakai T, Saigusa D, Kato K, Fukuuchi T, Koshiba S, Yamamoto M, Suzuki N.
    Life Sci; 2024 Jun 01; 346():122641. PubMed ID: 38614299
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. TP0463518, a novel inhibitor for hypoxia-inducible factor prolyl hydroxylases, increases erythropoietin in rodents and monkeys with a good pharmacokinetics-pharmacodynamics correlation.
    Kato S, Takayama N, Takano H, Koretsune H, Koizumi C, Kunioka EI, Uchida S, Takahashi T, Yamamoto K.
    Eur J Pharmacol; 2018 Nov 05; 838():138-144. PubMed ID: 30179610
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA, Johnson B, Oei C, Westerman M, Olbina G, de Zoysa J, Roger SD, Sahay M, Cross N, McMahon L, Guptha V, Smolyarchuk EA, Singh N, Russ SF, Kumar S, PHI112844 Investigators.
    Am J Kidney Dis; 2016 Jun 05; 67(6):861-71. PubMed ID: 26827289
    [Abstract] [Full Text] [Related]

  • 11. Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.
    Charles S, Süssenberger R, Settje T, Langston C, Lainesse C.
    J Vet Intern Med; 2024 Jun 05; 38(1):197-204. PubMed ID: 37740521
    [Abstract] [Full Text] [Related]

  • 12. Effects of Molidustat in the Treatment of Anemia in CKD.
    Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T.
    Clin J Am Soc Nephrol; 2019 Jan 07; 14(1):28-39. PubMed ID: 30559105
    [Abstract] [Full Text] [Related]

  • 13. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease.
    Kurata Y, Tanaka T, Nangaku M.
    Curr Opin Nephrol Hypertens; 2020 Jul 07; 29(4):414-422. PubMed ID: 32452915
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease.
    Sakashita M, Tanaka T, Nangaku M.
    Contrib Nephrol; 2019 Jul 07; 198():112-123. PubMed ID: 30991411
    [Abstract] [Full Text] [Related]

  • 18. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
    Landau D, London L, Bandach I, Segev Y.
    PLoS One; 2018 Jul 07; 13(5):e0196684. PubMed ID: 29738538
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A.
    Eur J Pharmacol; 2021 Dec 05; 912():174583. PubMed ID: 34678238
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.